RESUMEN
Infection of vascular prostheses, particularly in the central aortic position, is a growing challenge in vascular surgery. Beside the use of extra-anatomic prosthetic bypasses the need for anatomic reconstruction with infection-resistant materials is growing. The use of arterial allografts is an established method in many centres for in situ reconstruction. Used historically as the only option for vessel replacement, allografts were seldom used once the development of synthetic prostheses started. Use as a vascular graft in infected regions began in the 1990s. Discussions about the use of "fresh" allografts without preservation were terminated by order of the European Union in 2003 (although the long-term benefits have been foreseen). Currently, because of the German Tissue Act, only "cryopreserved" allografts can be used. Larger, partially controlled studies about the outcome after cryopreserved allograft transplantation have shown similar results to the use of silver prostheses, with a significantly lower prevalence of re-infection. Questions remain about the use of immunosuppression after human allograft transplantation. Immunological interactions are mainly involved in allograft degeneration. Aneurysmal changes (most commonly late degeneration of allografts) can be treated with endovascular procedures and therefore have no direct impact on long-term results. The availability of allografts in Europe tends to be restricted, but companies based outside the EU permit a good supply. The use of allografts in non-university institutions shows the wide acceptance of the material and its suitability for routine use in vascular surgery, even if the treatment of infected vascular prostheses in the central position remains associated with high morbidity and mortality.